Last week, Patexia released its second annual ANDA Litigation Intelligence Report in which we covered the rankings, statistics and comprehensive analysis of abbreviated new drug application (ANDA) and Hatch-Waxman stakeholders. We couldn’t help but notice the decline in ANDA filing activity that has begun, after reaching its peak in 2018. Year-over-year comparison of the ANDA data, as seen in the following chart, shows the trend in the last four years. We observe a considerable decline from 2018 to 2019 (a decline of 4.2 cases/month) followed by a smaller decline from 2019 to 2020 (2.7 cases/month) and the sharpest decline from 2020 to 2021 (5.3 cases/month) indicated by the data analyzed for the first half of 2021. In total, this represents a decline in ANDA case filings of about 36% from 2017 to 2021. The same trend is noticed with the number of the patents involved in these cases.
Recent Posts
- A New Era of Copyright Litigation in Hollywood: Revisiting Pirates of the Caribbean One Year Later
- Federal Circuit Vacates TTAB Decision as Arbitrary and Capricious
- ‘I Want to Thank You’: Who and What IP Stakeholders are Giving Thanks for This Year
- SCOTUS Declines Solving Circuit Split on Awarding Avoided Costs in Trade Secret Cases
- Supreme Court Again Denies Inventor’s Bid to End Alice/Mayo